期刊
JOURNAL OF PATHOLOGY
卷 254, 期 3, 页码 216-228出版社
WILEY
DOI: 10.1002/path.5678
关键词
liver fibrosis; hepatic stellate cells; LX‐ 2; autophagy; fibrosis resolution; statins
资金
- Instituto de Salud Carlos III, Ministerio de Economia y Competitividad [CIBER CB06/04/0071, PI19/838, EHD19PI03]
- Generalitat Valenciana [PROMETEO/2018/141, PROMETEO/2019/027, APOSTD/2019/050]
- Ministerio de Ciencia, Innovacion y Universidades [RTI2018-096748-B-I00, RTI2018-094436-B-I00]
- European Regional Development Fund of the European Union
- Ministerio de Educacion, Cultura y Deporte [FPU16/05896]
Liver fibrosis is a chronic liver disease that has a significant impact on public health and lacks specific pharmacological therapy. Hepatic stellate cells are fundamental mediators of fibrosis, with autophagy playing a key role in their activation. Autophagy has been shown to enhance the fibrogenic process and may serve as a potential therapeutic target for the treatment and prevention of liver fibrosis.
Liver fibrosis (LF) occurs as a result of persistent liver injury and can be defined as a pathologic, chronic, wound-healing process in which functional parenchyma is progressively replaced by fibrotic tissue. As a phenomenon involved in the majority of chronic liver diseases, and therefore prevalent, it exerts a significant impact on public health. This impact becomes even more patent given the lack of a specific pharmacological therapy, with LF only being ameliorated or prevented through the use of agents that alleviate the underlying causes. Hepatic stellate cells (HSCs) are fundamental mediators of LF, which, activated in response to pro-fibrotic stimuli, transdifferentiate from a quiescent phenotype into myofibroblasts that deposit large amounts of fibrotic tissue and mediate pro-inflammatory effects. In recent years, much effort has been devoted to understanding the mechanisms through which HSCs are activated or inactivated. Using cell culture and/or different animal models, numerous studies have shown that autophagy is enhanced during the fibrogenic process and have provided specific evidence to pinpoint the fundamental role of autophagy in HSC activation. This effect involves - though may not be limited to - the autophagic degradation of lipid droplets. Several hepatoprotective agents have been shown to reverse the autophagic alteration present in LF, but clinical confirmation of these effects is pending. On the other hand, there is evidence that implicates autophagy in several anti-fibrotic mechanisms in HSCs that stimulate HSC cell cycle arrest and cell death or prevent the generation of pro-fibrotic mediators, including excess collagen accumulation. The objective of this review is to offer a comprehensive analysis of published evidence of the role of autophagy in HSC activation and to provide hints for possible therapeutic targets for the treatment and/or prevention of LF related to autophagy. (c) 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据